Kazia Operating Cycle from 2010 to 2026
| KZIA Stock | USD 5.34 0.33 6.59% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 703.93 | Current Value 668.73 | Quarterly Volatility 88.5 K |
Check Kazia Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kazia Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 2.3 K or Selling General Administrative of 8.6 M, as well as many indicators such as Price To Sales Ratio of 212, Dividend Yield of 0.0 or Days Sales Outstanding of 669. Kazia financial statements analysis is a perfect complement when working with Kazia Therapeutics Valuation or Volatility modules.
Kazia | Operating Cycle | Build AI portfolio with Kazia Stock |
Analyzing Kazia Therapeutics's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing Kazia Therapeutics's current valuation and future prospects.
Latest Kazia Therapeutics' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Kazia Therapeutics Ltd over the last few years. It is Kazia Therapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kazia Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Kazia Operating Cycle Regression Statistics
| Arithmetic Mean | 25,810 | |
| Geometric Mean | 129.85 | |
| Coefficient Of Variation | 343.03 | |
| Mean Deviation | 44,789 | |
| Median | 201.84 | |
| Standard Deviation | 88,536 | |
| Sample Variance | 7.8B | |
| Range | 363.3K | |
| R-Value | 0.04 | |
| Mean Square Error | 8.3B | |
| R-Squared | 0 | |
| Significance | 0.87 | |
| Slope | 728.78 | |
| Total Sum of Squares | 125.4B |
Kazia Operating Cycle History
About Kazia Therapeutics Financial Statements
Kazia Therapeutics stakeholders use historical fundamental indicators, such as Kazia Therapeutics' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Kazia Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kazia Therapeutics' assets and liabilities are reflected in the revenues and expenses on Kazia Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kazia Therapeutics Ltd. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 703.93 | 668.73 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kazia Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kazia Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kazia Therapeutics Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kazia Therapeutics Ltd Stock:Check out the analysis of Kazia Therapeutics Correlation against competitors. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kazia Therapeutics. Expected growth trajectory for Kazia significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kazia Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (13.39) | Revenue Per Share | Quarterly Revenue Growth (0.27) | Return On Assets | Return On Equity |
Kazia Therapeutics's market price often diverges from its book value, the accounting figure shown on Kazia's balance sheet. Smart investors calculate Kazia Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Kazia Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Kazia Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kazia Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Kazia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.